Sana Biotechnology Inc vs Shell PLC — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Shell PLC trades at $86.69 (market cap $235.24B). The key difference: Shell PLC is far larger — about 269.2× Sana Biotechnology Inc's market cap, and Shell PLC pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SHEL | |
|---|---|---|
Market Cap | $873.84M | $235.24B |
Sector | Health | Energy |
52-Week High | $5.92 | $94.15 |
52-Week Low | $2.68 | $70.31 |
Enterprise Value | $848.03M | $287.77B |
Dividend Yield | — | 3.63% |
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →